Loading clinical trials...
Loading clinical trials...
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Conditions
Interventions
Clobetasol Propionate
Pharmacological Study
+2 more
Locations
22
United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Illinois CancerCare-Peoria
Peoria, Illinois, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
Siouxland Regional Cancer Center
Sioux City, Iowa, United States
Start Date
March 27, 2015
Primary Completion Date
September 1, 2017
Completion Date
March 2, 2023
Last Updated
June 18, 2025
NCT02600949
NCT04703101
NCT06696768
NCT04511039
NCT06051695
NCT06778863
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions